Top

Published in:

01-07-2019 | Cystectomy | Urology - Review

Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics

Authors: Aleksander Ślusarczyk, Piotr Zapała, Łukasz Zapała, Tomasz Piecha, Piotr Radziszewski

Published in: International Urology and Nephrology | Issue 7/2019

Abstract

Bacillus Calmette–Guerin (BCG) instillations are considered as a gold standard of therapy in high- and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Unfortunately, up to 40% of patients might experience treatment failure and even 15% of patients initially diagnosed with NMIBC will progress to muscle-invasive disease. Since patients, who fail to respond to BCG, are at particular risk of progression, immediate radical cystectomy (RC) is currently recommended to provide cancer control. However, immunotherapy in NMIBC management still evolves. Immune checkpoint inhibitors emerge as new immunotherapeutics, which in the future might be combined with BCG and may serve as an alternative to radical cystectomy in patients, who failed to respond to BCG alone or are at particular a priori risk of BCG failure, especially if RC is not a safe option. Therefore, there is an urgent need to identify NMIBC patients that will not benefit from BCG therapy and demand radical cystectomy. In the following review, we attempt to focus on several clinical and molecular factors and demonstrate the efforts directed to unravel their significance in BCG-failure risk assessment.

Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guerin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247–256PubMedCrossRef

Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Da Silva CF, Powell PH et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette–Guerin, and bacillus Calmette–Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766–773PubMedCrossRef

Zuiverloon TC, Zwarthoff EC (2016) Predicting response to intravesical bacillus Calmette–Guerin immunotherapy: are we moving forward? Eur Urol 69(2):201–202PubMedCrossRef

Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M (2003) Intravesical bacillus Calmette–Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 169(6):2110–2112PubMedCrossRef

Herr HW, Milan TN, Dalbagni G (2015) BCG-refractory vs BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol 33(3):108 e1–108 e4CrossRef

Barlow L, McKiernan J, Sawczuk I, Benson M (2009) A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette–Guerin therapy. BJU Int 104(8):1098–1102PubMedCrossRef

Cockerill PA, Knoedler JJ, Frank I, Tarrell R, Karnes RJ (2016) Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. BJU Int 117(3):456–462PubMedCrossRef

Di Lorenzo G, Perdona S, Damiano R, Faiella A, Cantiello F, Pignata S et al (2010) Gemcitabine versus bacille Calmette–Guerin after initial bacille Calmette–Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116(8):1893–1900PubMedCrossRef

Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette–Guerin. J Urol 182(4):1313–1317PubMedCrossRef

10.

Yates DR, Brausi MA, Catto JW, Dalbagni G, Roupret M, Shariat SF et al (2012) Treatment options available for bacillus Calmette–Guerin failure in non-muscle-invasive bladder cancer. Eur Urol 62(6):1088–1096PubMedCrossRef

11.

Patel S, Dinh T, Noah-Vanhoucke J, Rengarajan B, Mayo K, Clark PE et al (2015) Novel simulation model of non-muscle invasive bladder cancer: a platform for a virtual randomized trial of conservative therapy vs. cystectomy in BCG refractory patients. Bladder Cancer 1(2):143–150PubMedPubMedCentralCrossRef

12.

Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF (2018) ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer 18(1):1224PubMedPubMedCentralCrossRef

13.

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–475 (discussion 75–77) PubMedCrossRef

14.

Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette–Guerin: the CUETO scoring model. J Urol 182(5):2195–2203PubMedCrossRef

15.

Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS et al (2013) Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109(6):1460–1466PubMedPubMedCentralCrossRef

16.

Soukup V, Capoun O, Cohen D, Hernandez V, Burger M, Comperat E et al (2018) Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European association of urology non-muscle-invasive bladder cancer guidelines panel. Eur Urol Focus. https://doi.org/10.1016/j.euf.2018.11.005 CrossRefPubMed

17.

Holz S, Albisinni S, Gilsoul J, Pirson M, Duthie V, Quackels T et al (2017) Risk factor assessment in high-risk, bacillus Calmette–Guerin-treated, non-muscle-invasive bladder cancer. Res Rep Urol 9:195–202PubMedPubMedCentral

18.

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette–Guerin. Eur Urol 69(1):60–69PubMedCrossRef

19.

Boorjian SA, Zhu F, Herr HW (2010) The effect of gender on response to bacillus Calmette–Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 106(3):357–361PubMedCrossRef

20.

Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette–Guerin. Eur Urol 62(1):118–125PubMedCrossRef

21.

Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Roupret M et al (2013) Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 31(5):1029–1036PubMedCrossRef

22.

Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R et al (2008) Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53(5):992–1001PubMedCrossRef

23.

Gakis G, Stenzl A (2013) Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol 31(5):1059–1064PubMedCrossRef

24.

Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M et al (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29(1):43–51PubMedCrossRef

25.

Miyake M, Tatsumi Y, Gotoh D, Ohnishi S, Owari T, Iida K et al (2017) Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille Calmette–Guerin: a long-term follow-up study of a Japanese cohort. Int J Mol Sci 18:E2186. https://doi.org/10.3390/ijms18102186 CrossRefPubMed

26.

Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J (2015) Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 33(6):643–650PubMedCrossRef

27.

Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G et al (2014) The effect of age on the efficacy of maintenance bacillus Calmette–Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol 66(4):694–701PubMedCrossRef

28.

Nikolich-Zugich J (2018) The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol 19(1):10–19PubMedCrossRef

29.

Herr HW (2007) Age and outcome of superficial bladder cancer treated with bacille Calmette–Guerin therapy. Urology 70(1):65–68PubMedCrossRef

30.

Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D et al (2019) An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol. 37(3):507–514PubMedCrossRef

31.

Borges MD, Franca EL, Fujimori M, Silva SMC, de Marchi PGF, Deluque AL et al (2018) Relationship between proinflammatory cytokines/chemokines and adipokines in serum of young adults with obesity. Endocr Metab Immune Disord Drug Targets 18(3):260–267PubMedCrossRef

32.

Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A et al (2013) Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol 190(2):480–486PubMedCrossRef

33.

Lin Y, Wang Y, Wu Q, Jin H, Ma G, Liu H et al (2018) Association between obesity and bladder cancer recurrence: a meta-analysis. Clin Chim Acta 480:41–46PubMedCrossRef

34.

Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S (2018) Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. BMC Urol 18(1):90PubMedPubMedCentralCrossRef

35.

Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306PubMedCrossRef

36.

Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R et al (2018) Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer. Clin Genitourin Cancer 16(6):445–452PubMedCrossRef

37.

Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C et al (2016) Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol 34(11):483 e17–483 e24CrossRef

38.

Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B et al (2018) Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol 36(9):389–399PubMedCrossRef

39.

Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V et al (2016) The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette–Guerin. BJU Int 118(1):44–52PubMedCrossRef

40.

Zapala P, Dybowski B, Poletajew S, Bialek L, Niewczas A, Radziszewski P (2018) Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World J Surg Oncol 16(1):6PubMedPubMedCentralCrossRef

41.

Vasdev N, Dominguez-Escrig J, Paez E, Johnson MI, Durkan GC, Thorpe AC (2012) The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. Ecancermedicalscience 6:269PubMedPubMedCentral

42.

Ajili F, Kourda N, Karay S, Darouiche A, Chebil M, Boubaker S (2013) Impact of smoking intensity on outcomes of patients with non muscle invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol 37(4):273–277PubMedCrossRef

43.

Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ et al (2007) Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 100(2):281–286 (discussion 6) PubMedCrossRef

44.

Sfakianos JP, Shariat SF, Favaretto RL, Rioja J, Herr HW (2011) Impact of smoking on outcomes after intravesical bacillus Calmette–Guerin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int 108(4):526–530PubMedCrossRef

45.

Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G et al (2012) Smoking reduces the efficacy of intravesical bacillus Calmette–Guerin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol 62(6):1204–1206PubMedCrossRef

46.

Sopori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2(5):372–377PubMedCrossRef

47.

Hoffmann P, Roumeguere T, Schulman C, van Velthoven R (2006) Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355(25):2705–2707PubMedCrossRef

48.

Kamat AM, Wu X (2007) Statins and the effect of BCG on bladder cancer. N Engl J Med. 356(12):1276 (author reply-7) PubMedCrossRef

49.

Lipsky MJ, Badalato GM, Motamedinia P, Hruby GW, McKiernan JM (2013) The effect of fibrin clot inhibitors on the immunomodulatory efficacy of bacillus Calmette–Guerin therapy for non-muscle-invasive bladder cancer. Urology 81(6):1273–1278PubMedCrossRef

50.

Dal Moro F, Bovo A, Crestani A, Vettor R, Gardiman MP, Zattoni F (2015) Effect of hypertension on outcomes of high-risk patients after BCG-treated bladder cancer: a single-institution long follow-up cohort study. Medicine (Baltimore) 94(9):e589CrossRef

51.

Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras Gonzalez GM, Anderson R et al (2016) Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette–Guerin. Eur Urol 69(2):197–200PubMedCrossRef

52.

Kaempfer R, Gerez L, Farbstein H, Madar L, Hirschman O, Nussinovich R et al (1996) Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14(6):1778–1786PubMedCrossRef

53.

Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH, Zwarthoff EC (2012) Markers predicting response to bacillus Calmette–Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61(1):128–145PubMedCrossRef

54.

Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X et al (2017) High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: a long-term survival analysis. Oncoimmunology 6(2):e1265719PubMedPubMedCentralCrossRef

55.

Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM et al (2018) Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle invasive bladder cancer. Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.EPI-18-0893 CrossRef

56.

Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette–Guerin. J Urol 164(6):2129–2133PubMedCrossRef

57.

Poletajew S, Zapala P, Radziszewski P (2017) Safety and efficacy of intravesical bacillus Calmette–Guerin immunotherapy in patients with non-muscle-invasive bladder cancer presenting with asymptomatic bacteriuria: a systematic review. Urol Int 99(1):1–5PubMedCrossRef

58.

Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-Gonzalez G, Katz RL et al (2016) Novel fluorescence in situ hybridization-based definition of bacille Calmette–Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int 117(5):754–760PubMedCrossRef

59.

Bao Y, Tu X, Chang T, Qiu S, Yang L, Geng J et al (2018) The role of fluorescence in situ hybridization to predict patient response to intravesical bacillus Calmette–Guerin therapy for bladder cancer: a diagnostic meta-analysis and systematic review. Medicine (Baltimore). 97(36):e12227PubMedPubMedCentralCrossRef

60.

Liem E, Baard J, Cauberg ECC, Bus MTJ, de Bruin DM, Laguna Pes MP et al (2017) Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with bacillus Calmette–Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Med Oncol 34(10):172PubMedPubMedCentralCrossRef

61.

Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A et al (2009) Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette–Guerin immunotherapy. Eur Urol 55(6):1386–1395PubMedCrossRef

62.

Pichler R, Fritz J, Zavadil C, Schafer G, Culig Z, Brunner A (2016) Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette–Guerin therapy in bladder cancer. Oncotarget 7(26):39916–39930PubMedPubMedCentralCrossRef

63.

Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J et al (2017) Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother 66(4):427–440PubMedCrossRef

64.

Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN et al (2014) Predicting response to bacillus Calmette–Guerin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol 32(1):e23–e30CrossRef

65.

Cai T, Mazzoli S, Meacci F, Tinacci G, Nesi G, Zini E et al (2007) Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma. J Urol 178(5):1906–1911 (discussion 11–12) PubMedCrossRef

66.

Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG et al (2012) Prediction of response to bacillus Calmette–Guerin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med 4(3):459–464PubMedPubMedCentralCrossRef

67.

Du J, Wang SH, Yang Q, Chen QQ, Yao X (2016) p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J Surg Oncol 14:137PubMedPubMedCentralCrossRef

68.

He Y, Wang N, Zhou X, Wang J, Ding Z, Chen X et al (2018) Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. BMJ Open 8(4):e019635PubMedPubMedCentralCrossRef

69.

Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F et al (2009) Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 29(10):4201–4204PubMed

70.

Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stohr R et al (2014) Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol 65(1):218–226PubMedCrossRef

71.

El-Babouly IM, Desoky EAE, El Sayed D, Ali MM, Harb OA, Ragab A et al (2018) The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette–Guerin response in nonmuscle invasive bladder cancer. Urol Oncol 36(5):242 e9–242 e14CrossRef

72.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R et al (2018) High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother 67(3):403–412PubMedCrossRef

73.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP et al (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30(1):27–42PubMedCrossRef

74.

Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111(8):3110–3115PubMedCrossRef

75.

Hurst CD, Alder O, Platt FM, Droop A, Stead LF, Burns JE et al (2017) Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32(5):701 e7–715 e7CrossRef

76.

Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R et al (2016) Development and application of a microfluidics-based panel in the basal/luminal transcriptional characterization of archival bladder cancers. PLoS One 11(11):e0165856PubMedPubMedCentralCrossRef

77.

Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT et al (2018) Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch 472(5):749–758PubMedPubMedCentralCrossRef

Title: Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics
Authors: Aleksander Ślusarczyk
Piotr Zapała
Łukasz Zapała
Tomasz Piecha
Piotr Radziszewski
Publication date: 01-07-2019
Publisher: Springer Netherlands
Keyword: Cystectomy
Published in: International Urology and Nephrology / Issue 7/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02183-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2019

Correction to: The clinical utility of prostate cancer heterogeneity using texture analysis of multiparametric MRI

Morphologic changes after bladder neck intussusception in laparoscopic radical prostatectomy contribute to early postoperative continence

Androgen-deprivation therapy impairs left ventricle functions in prostate cancer patients

Validation of risk prediction tools in elderly patients who initiate dialysis

Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease

Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page